Ruolo della 18F-FDG PET/TCms nella valutazione della risposta precoce al trattamento del linfoma di Hodgkin

Translated title of the contribution: Role of [ 18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma

A. Orlacchio, O. Schillaci, E. Gaspari, F. Della Gatta, R. Danieli, F. Bolacchi, C. Ragano Caracciolo, A. Mancini, G. Simonetti

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: The authors evaluated the prognostic role of 18-fluoro- fluorodeoxyglucose positron emission tomography/multidetector computed tomography ([ 18F]-FDG PET/MDCT) in treating patients with Hodgkin's lymphoma (HL). Materials and methods: We retrospectively evaluated 132 patients with HL studied with PET/MDCT before the start of chemotherapy (CTX) for staging purposes and again after two CTX cycles with [doxorubicin (Adriblastin), bleomycin, vinblastine, dacarbazine (ABVD-] (interim PET/MDCT), at least 30 days after the end of the last CTX cycle and/or 3 months after the end of radiotherapy, if delivered (final PET-MDCT). Results: Interim PET-MDCT was negative in 104/132 patients (79%), and their final PET-MDCT showed complete remission in 102/104 (98%) of cases, with disease recurrence/persistence in two (2%). In the remaining 28 (21%) patients, interim PET-MDCT revealed an early response in 68% of cases and chemoresistance with disease progression in 32% of cases; in these 28 patients, final PET-MDCT showed a lack of response to treatment in 43% of cases (43%) and complete remission in 57% of cases. Statistical analysis of these data showed that interim PET-MDCT had a negative predictive value of 98% and a positive predictive value of 42%, with values of sensitivity, specificity and diagnostic accuracy of 85.7%, 86.4% and 86.4%, respectively. Conclusions: Interim PET-MDCT has a reliable prognostic role in diagnosis and treatment of patients with HL, as it helps predict which patients are more likely to achieve a complete response at the end of treatment. PET/MDCT may also lead to a change in treatment, with reduced treatment-related toxic effects and significantly reduced total costs.

Translated title of the contributionRole of [ 18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma
Original languageItalian
Pages (from-to)1250-1263
Number of pages14
JournalRadiologia Medica
Volume117
Issue number7
DOIs
Publication statusPublished - Oct 2012

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Fingerprint Dive into the research topics of 'Role of [ <sup>18</sup>F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this